ARCHIVES

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

This article is from The Cancer Letter archive.

Vol. 13 No. 15 | April 10, 1987

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI Last Month Are Listed

August 29, 2003

Xgeva Significantly Increases Bone Metastasis-Free Survival

May 27, 2011

In Breif: FDA Issues Uterine Cancer-Tamoxifin Warning; Fisher Declined Invitation To Speak At AACR

April 15, 1994

Study Finds No Benefit From CT In Lung Cancer; Advocacy Group Alleges “Delaying Tactic.”

March 9, 2007

ACS Board To Consider Proposal For Implementing Cancer Response System Nationwide; Could End CIS

June 7, 1985

FDA Approves Afinitor Tablets For Advanced Breast Cancer

August 31, 2012